3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Colorectal Neoplasms
11
Neoplasm Metastasis
10
Lung Neoplasms
7
Neoplasms
6
Colonic Neoplasms
6
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
2
Advanced Solid Tumor
2
Solid Tumors
1
Resectable Non-Small Cell Lung Cancer
1
Rectal Neoplasms
1
Kidney Neoplasms
1
Healthy Adults
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
aldesleukin
42
Sunitinib
39
Cyclophosphamide
30
Nivolumab
27
Everolimus
27
pembrolizumab
26
Interferon-alpha
25
Bevacizumab
22
Sorafenib
21
Interleukin-2
20
fludarabine phosphate
19
Filgrastim
18
Ipilimumab
17
Radiotherapy
16
Axitinib
16
Peripheral Blood Stem Cell Transplantation
15
Gemcitabine
15
cabozantinib
14
fludarabine
11
Radiosurgery
11
Doxorubicin
11
Carboplatin
11
temsirolimus
10
Etoposide
9
Chemotherapy, Adjuvant
9
sargramostim
8
belzutifan
8
atezolizumab
8
Fluorouracil
8
pazopanib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Kidney Neoplasms
×
adagrasib
×
Clear all
NCT06026410
2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1
Recruiting
300 enrolled